Work

MajesTEC-9: A randomized phase 3 study of teclistamab versus pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.

Year: 2023

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2023.41.16_suppl.tps8067

Authors: Cyrille Touzeau, Vania TM Hungria, Divaya Bhutani, Ola Landgren, Diego Vieyra, Yue Guo, Raluca Verona, Xin Miao, Mia Qi, Latisha Watkins, Priya Shah, Katherine Chastain, Ming Qi, Hang Quach

Institutions: Centre Hospitalier Universitaire de Nantes, Nantes Université, São Germano Oncologia, Columbia University Irving Medical Center, University of Miami, Sylvester Comprehensive Cancer Center, Janssen Research & Development (United States), Janssen (United Kingdom), The University of Melbourne, St Vincent's Hospital Melbourne

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Janssen Research and Development

OpenAlex ID: W4379280791

Cites:

Cited by: 12

Related to: 10